TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 3, Randomized, Double Blind, Placebo Controlled Study Of The Safety And Efficacy Of 2 Doses Of CP 690,550 In Patients With Active Rheumatoid Arthritis On Background DMARDS
Brief Summary: This Phase 3 study is intended to provide evidence that CP-690,550 dosed 5 mg BID and 10 mg BID is safe and effective when used in combination with a variety of traditional disease modifying antirheumatic drugs in adult patients with rheumatoid arthritis. It is intended to confirm the benefits of CP-690,550 in improving signs and symptoms and physical function that were observed in the Phase 2 rheumatoid arthritis studies.


Options:
A: Arm Label: Etanercept + Methotrexate; Type: ACTIVE_COMPARATOR; Interventions: Biological: Etanercept, Drug: Methotrexate | Arm Label: Etanercept Only; Type: EXPERIMENTAL; Interventions: Biological: Etanercept, Drug: Methotrexate | Intervention Type: BIOLOGICAL; Name: Etanercept; Assigned to Arm(s): Etanercept + Methotrexate, Etanercept Only | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Etanercept + Methotrexate, Etanercept Only
B: Arm Label: Active 5 mg; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Active 10 mg; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Placebo Sequence 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Placebo Sequence 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Active 5 mg | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Active 10 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Sequence 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Sequence 2
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: rituximab [MabThera/Rituxan] | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: rituximab [MabThera/Rituxan] | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: rituximab [MabThera/Rituxan] | Intervention Type: DRUG; Name: rituximab [MabThera/Rituxan]; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: rituximab [MabThera/Rituxan]; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: rituximab [MabThera/Rituxan]; Assigned to Arm(s): 3
D: Arm Label: Group I: Placebo + Methotrexate (MTX); Type: EXPERIMENTAL; Interventions: Drug: Golimumab, Other: Placebo, Drug: methotrexate (MTX) | Arm Label: Group II: Golimumab + Methotrexate (MTX); Type: PLACEBO_COMPARATOR; Interventions: Drug: Golimumab, Other: Placebo, Drug: methotrexate (MTX) | Intervention Type: DRUG; Name: Golimumab; Assigned to Arm(s): Group I: Placebo + Methotrexate (MTX), Group II: Golimumab + Methotrexate (MTX) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Group I: Placebo + Methotrexate (MTX), Group II: Golimumab + Methotrexate (MTX) | Intervention Type: DRUG; Name: methotrexate (MTX); Assigned to Arm(s): Group I: Placebo + Methotrexate (MTX), Group II: Golimumab + Methotrexate (MTX)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Sertindole Versus Risperidone Safety Outcome Study: a Randomised, Partially-blinded, Parallel-group, Active-controlled, Post-marketing Study
Brief Summary: The purpose of the study is to determine whether there is an increased all-cause mortality in sertindole-treated patients in comparison to patients treated with a well-known antipsychotic (risperidone) when used under normal marketed conditions in the treatment of schizophrenia.


Options:
A: Arm Label: Sertindole; Type: EXPERIMENTAL; Interventions: Drug: Sertindole | Arm Label: Risperidone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Risperidone | Intervention Type: DRUG; Name: Sertindole; Assigned to Arm(s): Sertindole | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): Risperidone
B: Arm Label: Naltrexone 50mg; Type: EXPERIMENTAL; Interventions: Drug: Naltrexone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Naltrexone 25mg; Type: EXPERIMENTAL; Interventions: Drug: Naltrexone | Intervention Type: DRUG; Name: Naltrexone; Assigned to Arm(s): Naltrexone 25mg, Naltrexone 50mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: Seroquel (quetiapine); Assigned to Arm(s): N/A
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: olanzapine versus risperidone | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: olanzapine versus risperidone | Intervention Type: DRUG; Name: olanzapine versus risperidone; Assigned to Arm(s): 1, 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Sertindole Versus Risperidone Safety Outcome Study: a Randomised, Partially-blinded, Parallel-group, Active-controlled, Post-marketing Study
Brief Summary: The purpose of the study is to determine whether there is an increased all-cause mortality in sertindole-treated patients in comparison to patients treated with a well-known antipsychotic (risperidone) when used under normal marketed conditions in the treatment of schizophrenia.


Options:
A: Arm Label: Sertindole; Type: EXPERIMENTAL; Interventions: Drug: Sertindole | Arm Label: Risperidone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Risperidone | Intervention Type: DRUG; Name: Sertindole; Assigned to Arm(s): Sertindole | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): Risperidone
B: Arm Label: Fondaparinux - UFH not indicated; Type: EXPERIMENTAL; Interventions: Drug: fondaparinux - UFH not indicated | Arm Label: Control - UFH not indicated; Type: PLACEBO_COMPARATOR; Interventions: Other: Control - UFH not indicated | Arm Label: Fondaparinux - UFH indicated; Type: EXPERIMENTAL; Interventions: Drug: Fondaparinux - UFH indicated | Arm Label: Control - unfractionated heparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Control - UFH | Intervention Type: DRUG; Name: fondaparinux - UFH not indicated; Assigned to Arm(s): Fondaparinux - UFH not indicated | Intervention Type: OTHER; Name: Control - UFH not indicated; Assigned to Arm(s): Control - UFH not indicated | Intervention Type: DRUG; Name: Fondaparinux - UFH indicated; Assigned to Arm(s): Fondaparinux - UFH indicated | Intervention Type: DRUG; Name: Control - UFH; Assigned to Arm(s): Control - unfractionated heparin
C: Intervention Type: DRUG; Name: Folic acid, vitamin B6 and B12 or placebo; Assigned to Arm(s): N/A
D: Arm Label: Rivaroxaban (Xarelto, BAY59-7939); Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): Rivaroxaban (Xarelto, BAY59-7939) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Double-Blind, Parallel-Group Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Desmoteplase in Subjects With Acute Ischemic Stroke
Brief Summary: The purpose of the study is to determine whether desmoteplase is effective and safe in the treatment of patients with acute ischaemic stroke when given within 3 to 9 hours from onset of stroke symptoms.


Options:
A: Arm Label: Desmoteplase; Type: EXPERIMENTAL; Interventions: Drug: Desmoteplase | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Desmoteplase; Assigned to Arm(s): Desmoteplase | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Desmoteplase | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Desmoteplase | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Desmoteplase; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Desmoteplase; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3
C: Arm Label: Desmoteplase, low dose; Type: EXPERIMENTAL; Interventions: Drug: Desmoteplase | Arm Label: Desmoteplase, high dose; Type: EXPERIMENTAL; Interventions: Drug: Desmoteplase | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Desmoteplase; Assigned to Arm(s): Desmoteplase, low dose | Intervention Type: DRUG; Name: Desmoteplase; Assigned to Arm(s): Desmoteplase, high dose | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: local interarterial recombinant tissue plasminogen activator | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: intravenous (IV) rt-PA | Intervention Type: DRUG; Name: local interarterial recombinant tissue plasminogen activator; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: intravenous (IV) rt-PA; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Comparison of Drug Eluting Balloon/Bare Metal Stent Versus Drug Eluting Stent Versus Bare Metal Stent for the Treatment of Patients With Acute ST-elevation Myocardial Infarction
Brief Summary: The investigators hypothesize that patients with Acute ST Elevation Myocardial Infarction may benefit from primary angioplasty with use of a drug eluting balloon/bare metal stent combination without impairing the process of normal vascular healing and endothelial function.

The goals of this study are:

1. To compare 6-month angiographic outcome after primary angioplasty using drug eluting balloon/bare metal stent combination versus drug eluting stent versus bare metal stent.
2. To compare stent apposition and stent endothelialization after primary angioplasty using drug eluting balloon/bare metal stent versus drug eluting stent versus bare metal stent.
3. To compare coronary endothelial function after primary angioplasty using drug eluting balloon/bare metal stent versus drug eluting stent versus bare metal stent.


Options:
A: Arm Label: Pharmacology Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bivalirudin, Drug: Unfractionated heparin | Arm Label: Stent Arm; Type: ACTIVE_COMPARATOR; Interventions: Device: Bare metal stent, Device: Paclitaxel-eluting stent | Intervention Type: DRUG; Name: Bivalirudin; Assigned to Arm(s): Pharmacology Arm | Intervention Type: DRUG; Name: Unfractionated heparin; Assigned to Arm(s): Pharmacology Arm | Intervention Type: DEVICE; Name: Bare metal stent; Assigned to Arm(s): Stent Arm | Intervention Type: DEVICE; Name: Paclitaxel-eluting stent; Assigned to Arm(s): Stent Arm
B: Arm Label: Everolimus-eluting stent; Type: ACTIVE_COMPARATOR; Interventions: Device: Everolimus-eluting stent | Arm Label: Bare-metal stent; Type: ACTIVE_COMPARATOR; Interventions: Device: Bare-metal stent | Arm Label: Biodegradable Polymer-DES; Type: EXPERIMENTAL; Interventions: Device: Biodegradable Polymer-DES | Intervention Type: DEVICE; Name: Everolimus-eluting stent; Assigned to Arm(s): Everolimus-eluting stent | Intervention Type: DEVICE; Name: Bare-metal stent; Assigned to Arm(s): Bare-metal stent | Intervention Type: DEVICE; Name: Biodegradable Polymer-DES; Assigned to Arm(s): Biodegradable Polymer-DES
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: Drug eluting balloon, Device: Bare metal stent | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: Drug eluting stent | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Device: Bare metal stent | Intervention Type: DEVICE; Name: Drug eluting balloon; Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: Bare metal stent; Assigned to Arm(s): 1, 3 | Intervention Type: DEVICE; Name: Drug eluting stent; Assigned to Arm(s): 2
D: Intervention Type: PROCEDURE; Name: Distal protection and drug eluting stent; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Vitamin D Supplementation During Pregnancy for Prevention of Asthma in Childhood: An Interventional Trial in the ABC (Asthma Begins in Childhood) Cohort
Brief Summary: The aim of this study is to prevent asthma symptoms (recurrent wheeze) in childhood by supplementation with high dose vitamin D to the mother during pregnancy. Participants are mothers and children of the ABC (Asthma Begins in Childhood) cohort. Mothers are recruited during pregnancy and receive daily supplement with 2400 IU of Vitamin D3 or placebo from week 24 og gestation to 1 week after delivery. In addition all mothers are advised to take the recommended dose of 400 IU vitamin D daily. The mothers in ABC also participate in an interventional trial with fish oil supplementation, and the vitamin D randomization is stratified by fish oil treatment group. The child is followed with acute and planned vits at the research unit, and wheeze is diagnosed according to predefined algorithms.


Options:
A: Arm Label: vitamin D; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vitamin D | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Vitamin D; Assigned to Arm(s): vitamin D | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
B: Intervention Type: OTHER; Name: Blood and breastmilk samples; Assigned to Arm(s): N/A
C: Arm Label: Vitamin D; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Cholecalciferol D3 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo tablet | Intervention Type: DIETARY_SUPPLEMENT; Name: Cholecalciferol D3; Assigned to Arm(s): Vitamin D | Intervention Type: OTHER; Name: Placebo tablet; Assigned to Arm(s): Placebo
D: Arm Label: monitored group; Type: EXPERIMENTAL; Interventions: Dietary Supplement: monitored vit D supplementation | Arm Label: standard group; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: standard vit D supplementation | Intervention Type: DIETARY_SUPPLEMENT; Name: monitored vit D supplementation; Assigned to Arm(s): monitored group | Intervention Type: DIETARY_SUPPLEMENT; Name: standard vit D supplementation; Assigned to Arm(s): standard group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Vitamin D Supplementation During Pregnancy for Prevention of Asthma in Childhood: An Interventional Trial in the ABC (Asthma Begins in Childhood) Cohort
Brief Summary: The aim of this study is to prevent asthma symptoms (recurrent wheeze) in childhood by supplementation with high dose vitamin D to the mother during pregnancy. Participants are mothers and children of the ABC (Asthma Begins in Childhood) cohort. Mothers are recruited during pregnancy and receive daily supplement with 2400 IU of Vitamin D3 or placebo from week 24 og gestation to 1 week after delivery. In addition all mothers are advised to take the recommended dose of 400 IU vitamin D daily. The mothers in ABC also participate in an interventional trial with fish oil supplementation, and the vitamin D randomization is stratified by fish oil treatment group. The child is followed with acute and planned vits at the research unit, and wheeze is diagnosed according to predefined algorithms.


Options:
A: Arm Label: Regimen A; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Regimen A calcium and iron/folic acid | Arm Label: Regimen B; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Regimen B calcium and iron/folic acid | Intervention Type: DIETARY_SUPPLEMENT; Name: Regimen A calcium and iron/folic acid; Assigned to Arm(s): Regimen A | Intervention Type: DIETARY_SUPPLEMENT; Name: Regimen B calcium and iron/folic acid; Assigned to Arm(s): Regimen B
B: Arm Label: Group A; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Arm Label: Group B; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D3 | Arm Label: Group C; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D3 | Arm Label: Group D; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D3 | Arm Label: Group E; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D3 | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D3; Assigned to Arm(s): Group B, Group C, Group D, Group E | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Group A
C: Arm Label: Vitamin D; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Cholecalciferol D3 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo tablet | Intervention Type: DIETARY_SUPPLEMENT; Name: Cholecalciferol D3; Assigned to Arm(s): Vitamin D | Intervention Type: OTHER; Name: Placebo tablet; Assigned to Arm(s): Placebo
D: Arm Label: 10 mcg Vitamin D3; Type: EXPERIMENTAL; Interventions: Dietary Supplement: 10 mcg Vitamin D3 | Arm Label: 20 mcg Vitamin D3; Type: EXPERIMENTAL; Interventions: Dietary Supplement: 20 mcg Vitamin D3 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: 10 mcg Vitamin D3; Assigned to Arm(s): 10 mcg Vitamin D3 | Intervention Type: DIETARY_SUPPLEMENT; Name: 20 mcg Vitamin D3; Assigned to Arm(s): 20 mcg Vitamin D3 | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Vitamin D Supplementation During Pregnancy for Prevention of Asthma in Childhood: An Interventional Trial in the ABC (Asthma Begins in Childhood) Cohort
Brief Summary: The aim of this study is to prevent asthma symptoms (recurrent wheeze) in childhood by supplementation with high dose vitamin D to the mother during pregnancy. Participants are mothers and children of the ABC (Asthma Begins in Childhood) cohort. Mothers are recruited during pregnancy and receive daily supplement with 2400 IU of Vitamin D3 or placebo from week 24 og gestation to 1 week after delivery. In addition all mothers are advised to take the recommended dose of 400 IU vitamin D daily. The mothers in ABC also participate in an interventional trial with fish oil supplementation, and the vitamin D randomization is stratified by fish oil treatment group. The child is followed with acute and planned vits at the research unit, and wheeze is diagnosed according to predefined algorithms.


Options:
A: Arm Label: cholecalciferol-400 IU; Type: ACTIVE_COMPARATOR; Interventions: Drug: cholecalciferol (vitamin D3), Drug: cholecalciferol | Arm Label: cholecalciferol 2000 IU; Type: EXPERIMENTAL; Interventions: Drug: cholecalciferol (vitamin D3), Drug: cholecalciferol | Arm Label: cholecalciferol 4000 IU; Type: EXPERIMENTAL; Interventions: Drug: cholecalciferol (vitamin D3), Drug: cholecalciferol | Intervention Type: DRUG; Name: cholecalciferol (vitamin D3); Assigned to Arm(s): cholecalciferol 2000 IU, cholecalciferol 4000 IU, cholecalciferol-400 IU | Intervention Type: DRUG; Name: cholecalciferol; Assigned to Arm(s): cholecalciferol 2000 IU, cholecalciferol 4000 IU, cholecalciferol-400 IU
B: Arm Label: Vitamin D; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Cholecalciferol D3 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo tablet | Intervention Type: DIETARY_SUPPLEMENT; Name: Cholecalciferol D3; Assigned to Arm(s): Vitamin D | Intervention Type: OTHER; Name: Placebo tablet; Assigned to Arm(s): Placebo
C: Arm Label: Study group; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: D Max drops | Arm Label: control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: D Max drops; Assigned to Arm(s): Study group
D: Arm Label: Vitamin D treatment; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D 3 cholecalciferol, Dietary Supplement: Vitamin D3 | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Vitamin D3 | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D 3 cholecalciferol; Assigned to Arm(s): Vitamin D treatment | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D3; Assigned to Arm(s): Vitamin D treatment, placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Placebo Controlled, Double Blind, Fixed Dose Study of the Efficacy and Safety of Eszopiclone in Children (6 to 11 Years) and Adolescents (12 to 17 Years) With Attention Deficit/Hyperactivity Disorder Associated Insomnia
Brief Summary: A multi center, randomized study to evaluate the efficacy and safety of eszopiclone compared to placebo in children (6-11 years of age, inclusive) and adolescents (12-17 years of age, inclusive) with attention deficit/hyperactivity disorder (ADHD) associated insomnia.


Options:
A: Arm Label: Low dose eszopiclone; Type: EXPERIMENTAL; Interventions: Drug: eszopiclone | Arm Label: High dose eszopiclone; Type: EXPERIMENTAL; Interventions: Drug: eszopiclone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: eszopiclone; Assigned to Arm(s): Low dose eszopiclone | Intervention Type: DRUG; Name: eszopiclone; Assigned to Arm(s): High dose eszopiclone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: 2mg eszopiclone (6-11yrs), 3mg eszopiclone (12-17yrs); Type: EXPERIMENTAL; Interventions: Drug: eszopiclone | Intervention Type: DRUG; Name: eszopiclone; Assigned to Arm(s): 2mg eszopiclone (6-11yrs), 3mg eszopiclone (12-17yrs) | Intervention Type: DRUG; Name: eszopiclone; Assigned to Arm(s): 2mg eszopiclone (6-11yrs), 3mg eszopiclone (12-17yrs)
C: Arm Label: Eszopiclone 1 mg; Type: EXPERIMENTAL; Interventions: Drug: Eszopiclone 1 mg | Arm Label: Eszopiclone 2 mg; Type: EXPERIMENTAL; Interventions: Drug: Eszopiclone 2 mg | Arm Label: Eszopiclone 3 mg; Type: EXPERIMENTAL; Interventions: Drug: Eszopiclone 3 mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Zolpidem Tartrate 10 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Zolpidem Tartrate 10 mg | Intervention Type: DRUG; Name: Eszopiclone 1 mg; Assigned to Arm(s): Eszopiclone 1 mg | Intervention Type: DRUG; Name: Eszopiclone 2 mg; Assigned to Arm(s): Eszopiclone 2 mg | Intervention Type: DRUG; Name: Eszopiclone 3 mg; Assigned to Arm(s): Eszopiclone 3 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Zolpidem Tartrate 10 mg; Assigned to Arm(s): Zolpidem Tartrate 10 mg
D: Arm Label: eszopiclone; Type: EXPERIMENTAL; Interventions: Drug: eszopiclone | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: eszopiclone; Assigned to Arm(s): eszopiclone | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): placebo

Answer: A